T cell receptor gamma variable 5Genealiases: TCRGV5 · V1S5
Q-omics provides the consensus-scored TRGV5 profile across patient tissues and cancer cell-line models. TRGV5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRGV5 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TRGV5 RNA expression shows 14,094 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where TRGV5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGV5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGV5 survival associations across molecular data types. TRGV5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGV5 RNA expression–survival associations across cancer types. High TRGV5 expression shows unfavorable associations in LGG, UVM and LUSC, but favorable associations in UCEC, SKCM and BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TRGV5 RNA expression.
This table summarizes TRGV5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRGV5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGV5 shows lower tumor expression in LUSC, PAAD and KICH and higher tumor expression in KIRC, STAD and BRCA. The KIRC box plot shows higher TRGV5 RNA expression in tumor versus normal tissue (log2 FC = +0.662, t-test p < 0.001).
This table shows molecular features associated with TRGV5 in patient tissues and cancer cell lines. In patient samples, TRGV5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
